GlassScriptPhysician profile
Kassandra N Johns
NPI 1649037409
$1,509.93
in general payments reported to CMS, 2019-2025
28 companies · $991 in 2025
The $991 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $519 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,509.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $224.56 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.57 | 2024-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $130.34 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $119.44 | 2024-2025 | Breztri, Airsupra, Fasenra |
| Abbvie INC. | $91.74 | 2024-2025 | |
| Pfizer INC. | $77.92 | 2024-2025 | |
| Axsome Therapeutics, INC. | $67.76 | 2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.05 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $61.27 | 2024-2025 | Rexulti |
| Amgen INC. | $59.53 | 2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $57.59 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boston Scientific Corporation | $52.07 | 2024-2025 | Watchman Flx |
| Exact Sciences Corporation | $31.49 | 2024 | Cologuard Collection Kit |
| Viatris Specialty LLC | $30.44 | 2025 | Yupelri |
| Astellas Pharma US INC | $29.02 | 2025 | Veozah |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $28.65 | 2025 | Smartvest |
| Merck Sharp & Dohme LLC | $28.11 | 2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Genentech USA, INC. | $27.00 | 2025 | Xolair |
| Daiichi Sankyo INC. | $22.97 | 2024 | Injectafer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.95 | 2025 | Lifevest |
| Grifols USA, LLC | $22.41 | 2025 | Prolastin-C Liquid |
| Dexcom, INC. | $21.99 | 2025 | Dexcom G6 Transmitter |
| Ani Pharmaceuticals, INC. | $21.90 | 2025 | Purified Cortrophin Gel |
| Esperion Therapeutics, INC. | $20.97 | 2024 | Nexletol |
| Philips North America LLC | $20.88 | 2025 | Vest Therapy Und |
| Emd Serono, INC. | $17.29 | 2025 | |
| Ucb, INC. | $16.50 | 2025 | Bimzelx |
| Phathom Pharmaceuticals, INC. | $9.52 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kassandra Johns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.